Journal Article

Anti-cytokine therapy in chronic heart failure: new approaches and unmet promises

Tiziana Bachetti, Laura Comini, Evasio Pasini and Roberto Ferrari

in European Heart Journal Supplements

Published on behalf of European Society of Cardiology

Volume 6, issue suppl_F, pages F16-F21
Published in print November 2004 | ISSN: 1520-765X
Published online November 2004 | e-ISSN: 1554-2815 | DOI: http://dx.doi.org/10.1016/j.ehjsup.2004.09.009
Anti-cytokine therapy in chronic heart failure: new approaches and unmet promises

Show Summary Details

Preview

Until some decades ago chronic heart failure (CHF) has been considered a haemodynamic disorder with neurohormonal activation. Thus, the therapeutic strategies were oriented to correct cardiovascular disarrangement and counteract neurohormones. Although these therapeutic interventions improved CHF prognosis, mortality and morbidity CHF related remained high. In the recent years experimental and clinical researches increased our knowledge on CHF pathophysiology. Specifically, the involvement of inflammatory cytokines in the progression of CHF become more and more evident.

Therefore, correction of cytokine network may represent a new therapeutic strategy approach in the management of CHF. However, results obtained from the first clinical trials with engineered anti-cytokine molecules, such as Infliximab and Etanercept, are discouraging.

More knowledge on the complex interplay among inflammatory molecules in heart failure will allow its transfer to the design of more effective therapeutic candidates.

The present review addresses current information on this controversial issue.

Journal Article.  4551 words.  Illustrated.

Subjects: Cardiovascular Medicine

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.